On December 5, 2023, Organon & Co. announced that Dr. Sandra Milligan will be departing from the Company on January 5, 2024. Effective December 1, 2023, Dr. Milligan ceased performing her functions as Head of Research and Development, and she will serve as a senior advisor to the Company until her departure on January 5, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.94 USD | +2.55% | +1.26% | +45.21% |
May. 08 | Organon Reports Pricing of $1 Billion Senior Notes Offering | MT |
May. 08 | Organon & Co. and Organon Foreign Debt Co-Issuer B.V. Announces Pricing of $1.0 Billion Senior Notes Offering | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.21% | 5.39B | |
+29.98% | 682B | |
+32.39% | 586B | |
-3.52% | 364B | |
+18.59% | 327B | |
+4.07% | 285B | |
+16.50% | 240B | |
+9.56% | 209B | |
-9.04% | 203B | |
+7.09% | 165B |
- Stock Market
- Equities
- OGN Stock
- News Organon & Co.
- Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024